Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corp, is a biopharmaceutical company that aims at developing proprietary drug delivery system and product candidates for the treatment of chronic hepatitis B infection (HBV). The company reports its operations under a single segment. Its HBV pipeline portfolio includes AB-729, HBV RNA destabilizer, and AB-101.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Arbutus Biopharma is advancing its proprietary drug delivery system and product candidates for the treatment of chronic hepatitis B infection (HBV). In FY2022, the company spent US$84.4 million its R&D activities and has 76 employees working towards its R&D. The company has a portfolio of 65 patent families, in the US and foreign countries. The patents cover its therapeutic HBV product candidates. Its patent portfolio also includes 150 issued patents throughout the world and an extensive portfolio of pending patent applications. Arbutus Biopharma owns and has in-licensed several issued patents in the US and other countries.